Video Version Only on HCPLive! 

In this episode of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, break down new key updates on cotntinous glucose monitoring (CGM) systems for diabetes, incuding the Dexcom G7, Libre App, and Medtronic Simplera Sync.

On April 10, 2025, the FDA granted clearance to the Dexcom G7 15-day continuous glucose monitoring (CGM) system for individuals aged 18 years and older with diabetes. The G7 CGM now boasts the longest-lasting CGM system with 15.5 days of wear and best-in-class accuracy with a mean absolute relative difference (MARD) of 8.0%.

Isaacs and Bellini discussed the sensor life of the G7 CGM, with Dexcom announcing only 73.9% of sensors lasted the full 15 days. When using the product per package labeling, approximately 26% of sensors may not last for the full 15 days.

With the launch of the new Libre app, Abbott is replacing the Libre 2 and 3 apps with a new all-in-one app that works with all Libre sensors. With the upcoming discontinuation of Libre 2 and 3 (non-Plus) sensors in the US by September 2025, intermittent scanning will be phased out, improving data continuity and aligning with American Diabetes Association (ADA) recommendations.

They also highlight Libre’s new integration with Glooko, allowing direct data syncing via Bluetooth from the app. This streamlines clinical workflows, supports EHR integration, and includes features like voice-activated carb logging, reducing both patient and provider burden.

On April 18, 2025, the FDA approved Medtronic’s Simplera Sync sensor for use with its MiniMed 780G insulin delivery system, expanding CGM options for users. The new all-in-one, fingerstick-free sensor offers simplified insertion and enhanced user flexibility while maintaining compatibility with the system’s Meal Detection™ technology and adaptive insulin algorithm. A limited US launch is planned for fall 2025.

Isaacs and Bellini noted this long-awaited update could improve access and uptake in the US., especially for newly diagnosed patients, thanks to easier usability and compatibility with Medtronic’s strong insulin delivery algorithm.

00:00:30 Dexcom G7 15-Day Sensor Approval

00:02:11 Challenges with Sensor Lifespan

00:06:00 Education and Replacement Process

00:09:27 Accuracy and FDA Approval Details

00:11:37 Libre's New Mobile App

00:16:55 Integration with Gluco

00:19:41 Medtronic's Simplera Sync Approval

00:23:03 Future Collaborations and Algorithms

00:28:05 Final Thoughts and Wrap-Up